Allergy Skin and Connective Tissue Diseases Allergy
Conditions
Interventions
Intervention arm: Hyposensitisation therapy with aluminium precipitated antigen extract, used subcutaneously. The duration of hyposensitisation therapy varies between patients, as each patient receive
Sponsors
Malmö University Hospital (Sweden)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Children and adults who will start their hyposensitisation therapy during 2007 and 2008 2. Written informed consent
Exclusion criteria
Exclusion criteria: Experienced anaphylaxis during skin tests.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| 1. To investigate the frequency of contact allergy in atopic children (contact allergy to aluminium and other sensitizers present in the European Patch Test Series) 2. To compare the contact allergy rated between atopic children and adults with and without atopic dermatitis (contact allergy to aluminium and other sensitisers present in the European Patch Test Series) 3. To make comparison between groups considering the following possible risk factors for developing persisting itching nodules with contact allergy to aluminium: 3.1. Doses 3.2. Sex 3.3. Age 3.4. Other medication/exposure | — |
Primary
| Measure | Time frame |
|---|---|
| 1. To estimate the proportion of children and adults who develop contact allergy to aluminium during the hyposensitisation therapy measured by patch testing 2. To compare the proportion of children and adults with positive patch test reactions to aluminum between groups, those with persistent nodules with or without itching and those without manifestations/symptoms All patch testing will be performed in close connection with the injections, which means on the same day or the following days. The patch test reader will be blinded - he/she will not know which patient has already received the hyposensitisation therapy and which has not (and will be receiving). | — |
Countries
Sweden
Outcome results
None listed